Dengue vaccines: progress and challenges

被引：84

作者：

Coller, Beth-Ann G. ^{[1
]}

Clements, David E. ^{[1
]}

机构：

[1] Merck & Co Inc, Vaccines Res, West Point, PA 19486 USA

来源：

CURRENT OPINION IN IMMUNOLOGY | 2011年 / 23卷 / 03期

关键词：

HEMORRHAGIC-FEVER; CELLULAR-IMMUNITY; DISEASE SEVERITY; SOUTHEAST-ASIA; CLINICAL-TRIAL; PUBLIC-HEALTH; SEROTYPES; VIRUS; ANTIBODIES; NAIVE;

D O I：

10.1016/j.coi.2011.03.005

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

With several dengue vaccine candidates progressing through clinical trials, several options for controlling this disease appear feasible. This would represent a major achievement and reflect decades of research and development activities. The challenges associated with the limited understanding of protective responses and those factors which determine disease severity remain, but with prospective studies ongoing in various dengue endemic areas and the initiation of dengue vaccine efficacy trials, immune responses are being evaluated in the context of protection and severe disease and these studies are highly likely to provide additional insights.

引用

页码：391 / 398

页数：8

共 66 条

[11] The Impact of the Demographic Transition on Dengue in Thailand: Insights from a Statistical Analysis and Mathematical Modeling [J].

Cummings, Derek A. T. ;

Iamsirithaworn, Sopon ;

Lessler, Justin T. ;

McDermott, Aidan ;

Prasanthong, Rungnapa ;

Nisalak, Ananda ;

Jarman, Richard G. ;

Burke, Donald S. ;

Gibbons, Robert V. .

PLOS MEDICINE, 2009, 6 (09)

[12] Cross-Reacting Antibodies Enhance Dengue Virus Infection in Humans [J].

Dejnirattisai, Wanwisa ;

Jumnainsong, Amonrat ;

Onsirisakul, Naruthai ;

Fitton, Patricia ;

Vasanawathana, Sirijitt ;

Limpitikul, Wannee ;

Puttikhunt, Chunya ;

Edwards, Carolyn ;

Duangchinda, Thaneeya ;

Supasa, Sunpetchuda ;

Chawansuntati, Kriangkrai ;

Malasit, Prida ;

Mongkolsapaya, Juthathip ;

Screaton, Gavin .

SCIENCE, 2010, 328 (5979) :745-748

[13] The live attenuated dengue serotype 1 vaccine rDEN1Δ30 is safe and highly immunogenic in healthy adult volunteers [J].

Durbin, Anna P. ;

McArthur, Julie ;

Marron, Jennifer A. ;

Blaney, Joseph E., Jr. ;

Thumar, Bhavin ;

Wanionek, Kim ;

Murphy, Brian R. ;

Whitehead, Stephen S. .

HUMAN VACCINES, 2006, 2 (04) :167-173

[14] rDEN2/4Δ30(ME), a live attenuated chimeric dengue serotype 2 vaccine, is safe and highly immunogenic in healthy dengue-naive adults [J].

Durbin, Anna P. ;

McArthur, Julie H. ;

Marron, Jennifer A. ;

Blaney, Joseph E. ;

Thumar, Bhavin ;

Wanionek, Kimberli ;

Murphy, Brian R. ;

Whitehead, Stephen S. .

HUMAN VACCINES, 2006, 2 (06) :255-260

[15] Serotype-Specific Differences in the Risk of Dengue Hemorrhagic Fever: An Analysis of Data Collected in Bangkok, Thailand from 1994 to 2006 [J].

Fried, Jessica R. ;

Gibbons, Robert V. ;

Kalayanarooj, Siripen ;

Thomas, Stephen J. ;

Srikiatkhachorn, Anon ;

Yoon, In-Kyu ;

Jarman, Richard G. ;

Green, Sharone ;

Rothman, Alan L. ;

Cummings, Derek A. T. .

PLOS NEGLECTED TROPICAL DISEASES, 2010, 4 (03)

[16] Asymptomatic Dengue Infection in a Cuban Population Confirms the Protective Role of the RR Variant of the FcγRIIa Polymorphism [J].

Garcia, Gissel ;

Sierra, Beatriz ;

Perez, Ana B. ;

Aguirre, Eglys ;

Rosado, Ileana ;

Gonzalez, Narjara ;

Izquierdo, Alienys ;

Pupo, Maritza ;

Ruiz, Didye ;

Diaz, Danay ;

Sanchez, Lizet ;

Marcheco, Beatriz ;

Hirayama, Kenji ;

Guzman, Maria G. .

AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2010, 82 (06) :1153-1156

[17] Mutations of an antibody binding energy hot spot on domain III of the dengue 2 envelope glycoprotein exploited for neutralization escape [J].

Gromowski, Gregory D. ;

Roehrig, John T. ;

Diamond, Michael S. ;

Lee, J. Ching ;

Pitcher, Trevor J. ;

Barrett, Alan D. T. .

VIROLOGY, 2010, 407 (02) :237-246

[18] The global emergence/resurgence of arboviral diseases as public health problems [J].

Gubler, DJ .

ARCHIVES OF MEDICAL RESEARCH, 2002, 33 (04) :330-342

[19] Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax™-DEN2) vaccine:: Phase I clinical trial for safety and immunogenicity [J].

Guirakhoo, Farshad ;

Kitchener, Scott ;

Morrison, Dennis ;

Forrat, Remi ;

McCarthy, Karen ;

Nichols, Richard ;

Yoksan, Sutee ;

Duan, Xiaochu ;

Ermak, Thomas H. ;

Kanesa-Thasan, Niranjian ;

Bedford, Philip ;

Lang, Jean ;

Quentin-Millet, Marie-Jose ;

Monath, Thomas P. .

HUMAN VACCINES, 2006, 2 (02) :60-67

[20] Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects [J].

Guy, Bruno ;

Nougarede, Nolwenn ;

Begue, Sarah ;

Sanchez, Violette ;

Souag, Nadia ;

Carre, Murielle ;

Chambonneau, Laurent ;

Morrisson, Dennis N. ;

Shaw, David ;

Qiao, Ming ;

Dumas, Rafaele ;

Lang, Jean ;

Forrat, Remi .

VACCINE, 2008, 26 (45) :5712-5721

← 1 2 3 4 5 6 7 →